What Фезам Treats: Main Uses and Benefits

The preparation is used in situations involving certain distressing symptoms related to both cognitive and functional domains. The components are utilized for symptomatic management in areas of vascular and vestibular functions.

Supporting Cognitive Clarity in Chronic Cerebral Conditions

This medication is commonly used to help with neurocognitive deficits such as memory loss, reduced concentration, and learning difficulties that generally accompany conditions like cerebral insufficiency. By addressing these symptom patterns, it provides support that helps ease the overall symptom burden on cognitive function. It is also applied in settings where short-term symptomatic assistance is needed for recovery following an ischemic stroke.

Managing Chronic Vertigo and Balance Instability

Фезам is commonly used across domains where additional symptomatic support is needed for recurrent vestibular and balance disorders. It is commonly used to help with symptom clusters that may become intense or disruptive, such as objective vertigo, associated nausea, and instability (e.g., in Ménière's syndrome). This symptomatic support contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Vertigo and Cognitive Strain
The medication is commonly used to help patients cope more steadily with the fluctuations of dizziness and balance while also supporting the overall symptom burden on mental performance associated with chronic vascular issues.

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Adults (Aged 18 years and older). Patients with mild-to-moderate renal function impairment are eligible, but use requires caution and monitoring.
• Populations for whom use is contraindicated: Use is strictly prohibited for patients with known hypersensitivity to Piracetam, Cinnarizine, or any component; severe renal impairment (kidney failure); acute cerebral hemorrhage (hemorrhagic stroke); and the neurological disorder Huntington's chorea.
• Age-related eligibility rules: The fixed-combination drug is primarily established for Adults. Use is not established or not recommended for children and adolescents under 18 years of age.
• Pregnancy and lactation eligibility status: Use is officially contraindicated during both pregnancy and breastfeeding periods due to safety concerns regarding the transfer of components to the fetus or infant.
• Eligibility-related restrictions: Patients with pre-existing conditions such as Parkinson's disease or a history of extrapyramidal disorders must use the medicine with caution, as symptoms may be aggravated. Caution is also noted for patients with low blood pressure or severe liver impairment.

---

Eligibility Classifications (High-Level)

• Eligibility severity classification: The official profile ranges from Contraindicated (absolute exclusion) to Restricted/Conditional Use (requiring caution and/or monitoring).
• Regulatory basis: Information is derived from the official Summary of Product Characteristics (SmPC) and similar national drug authority prescribing information.

Resulting Eligibility Structure

• Official eligibility statements: The medicine is strictly contraindicated for patients with severe kidney impairment, acute cerebral bleeding, and Huntington's chorea. Use is prohibited for pregnant and breastfeeding women.

Connection to the overall eligibility profile: Regulatory documents define eligibility by classifying individuals based on absolute contraindications relating to bleeding risk and specific neurological and organ health statuses, alongside conditional use mandates for patients with pre-existing conditions such as Parkinson’s or moderate organ impairment, ensuring the constraints are solely based on labeled safety margins.

Interactions with Other Medicines and Products

The officially documented interaction profile for Фезам is defined by the activities of its two components, Piracetam and Cinnarizine, as described in regulatory documents.

Pharmacodynamic Interactions

Co-administration with substances that affect the central nervous system (CNS) requires specific consideration. The Cinnarizine component may potentiate the sedative effects when used concurrently with alcohol or CNS depressants, including tricyclic antidepressants. Conversely, the Piracetam component’s influence on platelet function may increase the risk of bleeding when combined with anti-platelet agents or anticoagulants, such as clopidogrel. Furthermore, the Cinnarizine component may mask ototoxic symptoms caused by aminoglycosidic antibiotics.

Pharmacokinetic and Population-Based Notes

The Cinnarizine component undergoes metabolism primarily mediated by the Cytochrome P450 2D6 (CYP2D6) enzyme pathway, which may affect its exposure when combined with CYP2D6-modifying medicines. Regulatory sources also note that food intake may decrease the peak plasma concentration (Cmax) and prolong the time to Cmax (Tmax) of Piracetam. Caution is advised for use in patients with renal impairment, as Piracetam is largely eliminated by the kidneys.

The Mechanism of Action of Фезам

Фезам is a fixed-dose combination containing two pharmacologically distinct agents, Piracetam and Cinnarizine, each contributing to the overall pharmacodynamic profile through different biological targets.

Piracetam modulates neuronal and vascular functions primarily by interacting with the polar heads of membrane phospholipids. This interaction influences membrane fluidity and stability, which in turn facilitates the function of membrane-bound proteins, including those involved in neurotransmission (e.g., cholinergic and glutamatergic systems). Piracetam is also associated with improved erythrocyte deformability and reduced platelet adhesion to the vascular endothelium, promoting microcirculation.

Cinnarizine acts as a selective L-type and T-type voltage-gated calcium channel blocker. By inhibiting calcium ion influx into vascular smooth muscle cells, it induces vasorelaxation, particularly in the cerebral and peripheral vasculature. Furthermore, Cinnarizine functions as an antagonist at histamine H1 receptors and, to a lesser extent, dopamine D2 receptors, influencing signal transmission, particularly within the central vestibular system.

The administration of Фезам (Piracetam 400 mg / Cinnarizine 25 mg) involves specific parameters concerning dosage, frequency, and duration. The fixed-dose combination is utilized for oral administration as a hard capsule, delivering 400 mg of Piracetam and 25 mg of Cinnarizine in a single unit.

The standard regimen for adults is to take one to two capsules per dose, administered three times a day (TID). The medicine may be taken independently of food intake. The therapeutic protocol defines a time-bound course, typically lasting between one to three months.

Special Procedural Conditions

A key condition specifies that the product should not be used for more than three consecutive months without interruption. Treatment courses may be repeated two to three times annually.

Population-Specific Administration Rules

Instructions detail adjustments for specific patient groups:

• Children (over 5 years): The regimen is typically modified to one to two capsules, administered one to two times daily.
• Renal Impairment: For patients with mild or moderate renal insufficiency, management involves a reduction in the therapeutic dose or a prolongation of the interval between doses.
• Older Adults (over 65 years): Prolonged use in this population necessitates the regular control of creatinine clearance to guide appropriate dose modification.

Research Evidence / Overview of Studies for Фезам

---

Evidence for Use in Chronic Cerebral Conditions

The fixed combination of Piracetam and Cinnarizine was studied for its application in conditions characterized by fluctuating or episodic manifestations of Chronic Cerebral Insufficiency. Research examined adult and older adult populations through a mix of short- to intermediate-term Randomized Controlled Trials (RCTs) and observational studies. Researchers aimed to measure changes in Neurological Status and assess outcomes reflecting daily functioning or activity level, such as test scores used to assess cognitive function, indicators of Cerebral Blood Flow, and patient-reported outcomes. Findings related to outcomes describing episodic or acute changes data show patterns related to changes in measurements of cerebral circulation. This research provides context, but not individual predictions, about how symptoms were monitored over the study intervals.

Evidence for Use in Recovery Following Ischemic Stroke

The combination was evaluated in patients during the recovery phase after an Ischemic Stroke. The research focused on assessing changes in Overall Neurological Outcome and outcomes reflecting daily functioning or activity level. Much of the evidence in this setting research examined the Piracetam component alone in large-scale trials, while the fixed combination has been a subject of smaller clinical trials. Findings describe patterns observed in the studies concerning recovery markers. Comparative evidence is lacking to definitively separate the impact of the combination therapy from standard post-stroke rehabilitation. The data are still emerging regarding optimal use in different patient groups.

---

What is Still Uncertain About the Combination's Research

The research evidence highlights what is known — and what is still uncertain. The sample sizes were modest in many controlled studies, which means the results apply only to the populations studied and may not generalize broadly. Evidence quality varies across studies, particularly due to differences in geographical origin and methodological standards over time. Long-term effects are not fully established, and certainty remains low regarding the durability of any observed patterns of response. Research is ongoing to provide clearer and more extensive data on long-term functional outcomes.

Common questions about Фезам (FAQ)

Q: Is Фезам used for memory or concentration issues?

The official common use of the drug is described as supporting cognitive function and balance. The Piracetam component is often classified as a nootropic compound, generally studied for its influence on neuronal function.

Q: How is Фезам different from other medicines used for cerebral circulation?

Official documents describe Фезам as a multimodal fixed-combination drug, integrating the nootropic component Piracetam with the cerebro-vasodilator Cinnarizine. This combination approach is intended to address both neuronal and circulatory aspects, distinguishing it from single-agent therapies.

Q: Can Фезам be used for symptoms related to motion sickness or dizziness?

Official information notes the Cinnarizine component has labyrinthine suppressant properties, meaning it acts on the parts of the inner ear associated with the balance system. The drug's common use is officially described as supporting cognitive function and balance.

Q: Are there specific over-the-counter supplements or medicines that should be mentioned to a doctor before taking Фезам?

Official label information indicates caution regarding co-administration with certain classes of substances. These include medicines classified as CNS depressants (due to the potential for enhanced sedation) and substances that may influence platelet function, such as anti-platelet agents (which carry a risk of increased bleeding).

Q: Are there any dietary restrictions mentioned in relation to Фезам?

Official product information states that the medicine may be taken independently of food intake. There is a note that taking it with food may slightly decrease and delay the peak concentration of the Piracetam component.

Q: Does official research evidence exist for Фезам's use in children?

The research evidence overview focuses on adult and older adult populations through a mix of short- to intermediate-term clinical trials. Specific studies assessing outcomes of the combined drug’s use in children are not described in the regulatory summary.

Q: What is the risk of dependence or addiction with Фезам?

According to the official safety information, the risk of dependence or addiction is not mentioned in the documented side effects, safety restrictions, or warnings for this medicine.

Q: Is it possible for Фезам to cause insomnia?

Insomnia (difficulty falling or staying asleep) is not listed in the official adverse reactions. Conversely, Hypersomnia (excessive sleeping) is listed as an Uncommon side effect.

Q: Are there any known issues combining Фезам with common pain relievers?

Official warnings note that co-administration with substances that influence platelet function, such as anti-platelet agents, may lead to a potential increase in the risk of bleeding. This caution is noted in the official interaction profile.

Q: Why do some people report feeling headaches when they start taking Фезам?

Headaches are not listed in the formally documented adverse reactions (Common, Uncommon, or Not Known) that are provided in the official safety information.

Q: What information is provided about Фезам and liver function?

Information about liver function or special precautions related to it is not addressed in the official safety restrictions or dosing adjustments provided. The regulatory information does, however, provide detailed adjustments related to kidney function.

Q: Does Фезам have any known interaction with vitamins or mineral supplements?

The officially documented interaction profile for Фезам does not list any known interaction with common vitamins or mineral supplements. The profile focuses on other prescription drug classes and alcohol.

Q: What are the main risks if Фезам is used by someone who is ineligible?

Regulatory documents state that using the medicine when a formal contraindication exists (such as cerebral haemorrhage or severe renal impairment) is formally prohibited, as the risks associated with those conditions are incompatible with the drug’s use.

Q: What happens if you suddenly stop taking Фезам?

The official safety information does not contain any warnings regarding withdrawal or discontinuation effects that occur specifically when stopping the medicine.

Q: Can Фезам affect the results of a laboratory test?

The Cinnarizine component may affect clinical monitoring by potentially masking symptoms of ear damage (ototoxicity) caused by concurrent use of certain antibiotics.

Q: Are there any reported studies on the use of Фезам in older adults?

Official research has examined adult and older adult populations. Official instructions emphasize the need for regular control of creatinine clearance (a measure of kidney function) during prolonged use in this population.

Q: Is it common to feel a slight stomach upset when starting Фезам?

Official product information lists gastrointestinal symptoms, such as nausea, vomiting, and upper abdominal pain, as common side effects. This means they are experienced by 1 to 10 users in 100, according to documented frequency data.

Q: Is there a known effect of Фезам on blood pressure?

The Cinnarizine component of Фезам acts as a calcium channel blocker, and its mechanism of action involves inducing vasorelaxation (the relaxation of blood vessel walls). This effect occurs primarily in the cerebral and peripheral vasculature.

Q: Can Фезам cause changes in mood or behavior?

Documented side effects include nervousness and depression, which are listed as Common or Uncommon reactions. Other changes, such as agitation, confusion, and hallucinations, have also been noted, although their frequency is not known.

How to Store and Dispose of Фезам

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and safety of Фезам (Phezam).

Storage Conditions

Requirement	Official Statement
Temperature	Store at a temperature not exceeding 25 C (Controlled Room Temperature).
Protection	Keep in the original, tightly closed packaging, and protect from moisture.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Regulatory instructions specify that unused or expired Фезам must not be disposed of via household waste or wastewater, as these measures help to protect the environment. Patients should return the medicine to a pharmacist for environmentally safe discarding of pharmaceutical products.